Ngm Biopharmaceuticals EBIT

Ngm Biopharmaceuticals (NGM) currently reports a EBIT of $-150M as of December 2023. That compares with $-170M in the prior-year period — up 8.5% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Ngm Biopharmaceuticals's EBIT history and peer comparisons.

Ngm Biopharmaceuticals's EBIT increased from $-170M to $-150M — a 8.5% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ngm Biopharmaceuticals's EBIT of $-150M is lower than the Healthcare sector average of $22B. That is roughly 100.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Ngm Biopharmaceuticals reported $-150M in EBIT as of December 2023. That compares with $-170M in the prior-year period — up 8.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-150M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Ngm Biopharmaceuticals, and consider following NGM for alerts when major investors trade the stock.